Trial Profile

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Seribantumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Cholangiocarcinoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Focus Proof of concept; Therapeutic Use
Acronyms CRESTONE
Sponsors Elevation Oncology

Most Recent Events

19 Sep 2024 Status changed to discontinued, according to ClinicalTrials.gov: US National Institutes of Health
07 Aug 2023 Planned End Date changed from 1 Jun 2023 to 1 Mar 2025.
07 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com